Atherosclerosis

Atherosclerosis is not "clogged arteries." It is a decades-long inflammatory process driven by lipid-laden particles burrowing into artery walls, and it underlies most heart attacks, strokes, and a meaningful share of cognitive decline. Getting the mechanism right matters, because prevention and reversal strategies follow directly from it.

The causal chain starts with apoB particles

LDL and other apoB-containing lipoproteins cause atherosclerotic cardiovascular disease. Not associate with it, cause it. That conclusion comes from Mendelian randomization studies, clinical trials, and the 2017 European Atherosclerosis Society consensus statement [1]. Among the metrics used to track this burden, apoB particle count outperforms LDL cholesterol and particle size as a predictor of risk [2]. Lowering LDL reduces cardiovascular events proportionally, at roughly 22% per mmol/L reduction in meta-analyses of statin trials [3]. Lipoprotein(a) adds a separate, genetically determined, causal layer on top of LDL [4].

How plaque builds

Verhoeven's analysis of the pathogenesis describes six interlocking steps. ApoB particles (LDL, VLDL remnants, IDL, Lp(a)) cross the endothelium and bind to subendothelial proteoglycans; more circulating particles means more retention [5, 6]. The causal basis for this rests on the primary evidence above [1, 2]. Once retained, those particles oxidize within the artery wall, not in plasma. Oxidized LDL then triggers the immune cascade, a point emphasized by lipidologist Tom Dayspring [7]. Monocytes arrive, differentiate into macrophages, and engulf oxidized LDL through scavenger receptors. Overwhelmed, they become foam cells: inflamed, dysfunctional, and stuck [8, 5]. When foam cells die, they release cholesterol crystals and chemokines that deepen a necrotic core, making the plaque less stable [8, 9]. Smooth-muscle cells then lay down collagen over the atheroma, forming a fibrous cap. A thick cap means a stable plaque; a thin one ruptures [10, 8]. Late in the process, calcium deposits into the plaque, the final, more stable form [10].

Arteries are specifically vulnerable because their walls contain more proteoglycans with higher LDL affinity, and arterial cells respond to mechanical pressure. Verhoeven's analysis notes that saphenous veins grafted into arterial positions upregulate those same proteoglycans and develop atherosclerosis over time [11].

Not all plaque is equally dangerous

Non-calcified ("soft") plaque carries the highest rupture risk but is also the most amenable to reversal. Calcified plaque is structurally stable but fixed. Mixed plaque sits in between and carries the highest overall danger. James O'Keefe has described a higher coronary artery calcium (CAC) score from drug-induced calcification of previously soft plaque as "fossil evidence" of past inflammation [12]. Verhoeven's analysis supports the view that this shift, soft to calcified, is net-positive rather than worsening [10].

A 23-study meta-analysis quantifies the link between plaque change and hard outcomes: each roughly 1% reduction in percent atheroma volume corresponds to approximately a 19% lower rate of major adverse cardiovascular events [13].

Plaque and the brain

Animal data introduce a concerning pathway beyond direct stroke risk. In ApoE-knockout mice with surgically induced cerebral hypoperfusion, foam cells in arteries released exosomes that traveled to the brain, bound microglia, and caused white-matter injury independent of direct vascular effects [14]. No human longitudinal data confirm this chain yet, so it remains preliminary. The mechanism is biologically plausible and warrants further study.

An emerging association

Microplastic particles have been found inside carotid plaques, and patients with detectable microplastics had a hazard ratio of 4.53 for major cardiovascular events compared with those without [15]. That is an association; no mechanism has been confirmed, and the field is early.

Where the evidence is contested

CAC score interpretation after statin therapy. A higher CAC reading in a patient on statins can reflect calcification of previously soft plaque, structurally a good outcome, or genuine new plaque burden, which would not be. Verhoeven's analysis favors the net-positive interpretation [10], and O'Keefe frames calcified plaque as stable "fossil" disease [12]. No randomized trial has directly tested whether drug-induced CAC progression translates to better outcomes than CAC stability, so the reassuring framing, while mechanistically reasonable, is not yet settled by hard endpoint data.

ApoB vs. LDL-C for clinical decision-making. The evidence that apoB is a superior driver is well-established [2], but most cardiovascular outcome trials were built around LDL-C targets. Guidelines differ on whether apoB should replace or supplement LDL-C in practice, and that clinical translation debate is ongoing.

References

1. Ference et al. 2017, Eur Heart J — LDL causes ASCVD (EAS consensus) · PubMed 28444290
2. Marston et al. 2022, JAMA Cardiol — apoB primary risk driver · PubMed 34773460
3. CTT/Baigent 2010, Lancet — statin LDL-lowering meta-analysis · PubMed 21067804
4. Kamstrup et al. 2009, JAMA — genetic Lp(a) & MI (MR) · PubMed 19509380
5. raw/physionic/physionic-exercise-hiit-plaque*.txt
6. Physionic — Exercise-plaque paradox (athlete plaque type)
7. raw/attia/attia24-dayspring-lpa-inflammation-oxldl-part5.txt
8. raw/physionic/physionic-mineral-deficiency-calcified-arteries.txt
9. Physionic — Why plaque in arteries not veins (GAG composition)
10. raw/physionic/physionic-at-home-test-find-plaque.txt
11. raw/physionic/physionic-toxic-protein-clogging-arteries-kidneys.txt
12. Attia/O'Keefe — CVD risk from too much exercise (ep. 134)
13. Iatan 2023 — 23-study meta-analysis: 1% PAV → 19% MACE · PubMed 37647074
14. Zhang H et al. 2025 Cell Metab — foam cell exosomes → miR-101-3p → Nrf2 → Slc2a1 → microglial metabolic dysfunction → white matter injury (ApoE−/−… · PubMed 40345179
15. Marfella 2024 NEJM — MNPs in carotid plaque; HR 4.53 · PubMed 38446676